| Investor | Two Seas Capital LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Two Seas Capital LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G | PAVM / PAVmed Inc. | 657,219 | |||||
| 2026-05-15 | 13G/A | MDRX / Veradigm Inc. | 7,469,931 | 8,943,265 | ||||
| 2026-05-15 | 13G/A | ABUS / Arbutus Biopharma Corporation | 12,589,158 | 18,557,543 | ||||
| 2026-04-23 | 13D/A | 739190106 / POWER and DIGITAL INFRASTRUCTURE ACQUISITION CORP | 17,918,778 | 13,984,778 | ||||
| 2026-04-17 | 13G | NKTR / Nektar Therapeutics | 1,959,178 | |||||
| 2026-04-16 | 13D/A | 739190106 / POWER and DIGITAL INFRASTRUCTURE ACQUISITION CORP | 17,466,679 | 17,918,778 | ||||
| 2026-04-13 | 13D | OMEX / Odyssey Marine Exploration, Inc. | 5,084,883 | 5,857,448 | ||||
| 2026-03-20 | 13D/A | 739190106 / POWER and DIGITAL INFRASTRUCTURE ACQUISITION CORP | 17,466,679 | |||||
| 2026-03-04 | 13D/A | CORZ / Core Scientific, Inc. | 20,697,679 | 18,716,679 | ||||
| 2026-02-19 | 13D/A | CORZ / Core Scientific, Inc. | 22,472,467 | 20,697,679 | ||||
| 2026-02-17 | 13G/A | AVDL / Avadel Pharmaceuticals plc | 6,155,074 | 0 | ||||
| 2026-02-17 | 13G/A | CLMT / Calumet, Inc. | 6,752,538 | 8,098,229 | ||||
| 2026-02-17 | 13G/A | MDRX / Veradigm Inc. | 5,823,328 | 7,469,931 | ||||
| 2026-02-17 | 13G/A | ABUS / Arbutus Biopharma Corporation | 10,443,317 | 12,589,158 | ||||
| 2026-01-20 | 13D/A | CORZ / Core Scientific, Inc. | 25,002,467 | 22,472,467 | ||||
| 2025-12-23 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 7,061,854 | 6,211,854 | ||||
| 2025-12-18 | 13D/A | CORZ / Core Scientific, Inc. | 24,620,261 | 25,002,467 | ||||
| 2025-12-10 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 9,254,152 | 7,061,854 | ||||
| 2025-12-01 | 13D/A | CORZ / Core Scientific, Inc. | 24,721,800 | 24,620,261 | ||||
| 2025-11-17 | 13D/A | CORZ / Core Scientific, Inc. | 18,323,377 | 24,721,800 | ||||
| 2025-11-14 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 3,154,808 | 5,084,883 | ||||
| 2025-11-14 | 13G | MDRX / Veradigm Inc. | 5,823,328 | |||||
| 2025-11-14 | 13G/A | ESPR / Esperion Therapeutics, Inc. | 9,954,975 | 9,749,724 | ||||
| 2025-11-14 | 13G/A | ADAPY / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) | 135,484,206 | 0 | ||||
| 2025-11-14 | 13G/A | CLMT / Calumet, Inc. | 4,497,609 | 6,752,538 | ||||
| 2025-11-14 | 13G/A | TDAY / USA TODAY Co., Inc. | 11,230,621 | 14,180,621 | ||||
| 2025-11-05 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 10,329,152 | 9,254,152 | ||||
| 2025-10-31 | 13D/A | CORZ / Core Scientific, Inc. | 19,902,624 | 18,323,377 | ||||
| 2025-10-09 | 13D/A | CORZ / Core Scientific, Inc. | 19,122,842 | 19,902,624 | ||||
| 2025-09-05 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 11,662,308 | 10,329,152 | ||||
| 2025-08-13 | 13G | ESPR / Esperion Therapeutics, Inc. | 6,584,278 | 9,954,975 | ||||
| 2025-08-13 | 13G | TDAY / USA TODAY Co., Inc. | 11,230,621 | |||||
| 2025-08-13 | 13G | CLMT / Calumet, Inc. | 4,497,609 | |||||
| 2025-08-13 | 13G/A | ADAPY / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) | 123,178,110 | 135,484,206 | ||||
| 2025-08-13 | 13G/A | AVDL / Avadel Pharmaceuticals plc | 4,946,449 | 6,155,074 | ||||
| 2025-08-13 | 13G | ABUS / Arbutus Biopharma Corporation | 8,387,388 | 10,443,317 | ||||
| 2025-08-13 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 2,953,690 | 3,154,808 | ||||
| 2025-08-08 | 13D | CORZ / Core Scientific, Inc. | 19,122,842 | |||||
| 2025-08-08 | 13D | CORZ / Core Scientific, Inc. | 19,122,842 | |||||
| 2025-07-29 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 12,084,677 | 11,662,308 | ||||
| 2025-07-14 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 12,072,398 | 12,084,677 | ||||
| 2025-06-18 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 11,880,926 | 12,072,398 | ||||
| 2025-05-22 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 11,579,819 | 11,880,926 | ||||
| 2025-05-15 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 2,947,747 | 2,953,690 | ||||
| 2025-05-15 | 13G/A | ADAPY / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) | 89,010,876 | 123,178,110 | ||||
| 2025-05-15 | 13G | AVDL / Avadel Pharmaceuticals plc | 4,946,449 | |||||
| 2025-03-04 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 12,007,514 | 11,579,819 | ||||
| 2025-02-14 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 1,816,384 | 2,947,747 | ||||
| 2025-02-14 | 13G | ADAPY / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) | 89,010,876 | |||||
| 2025-01-17 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 13,030,027 | 12,007,514 | ||||
| 2024-11-14 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 2,082,638 | 1,816,384 | ||||
| 2024-11-14 | 13G/A | ESPR / Esperion Therapeutics, Inc. | 7,686,120 | 6,584,278 | ||||
| 2024-11-14 | 13G/A | ABUS / Arbutus Biopharma Corporation | 9,041,927 | 8,387,388 | ||||
| 2024-10-17 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 13,260,025 | 13,030,027 | ||||
| 2024-06-21 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 13,555,139 | 13,260,025 | ||||
| 2024-03-29 | 13D/A | INDV / Indivior Pharmaceuticals, Inc. | 13,670,312 | 13,555,139 | ||||
| 2024-02-14 | 13G/A | ESPR / Esperion Therapeutics, Inc. | 7,922,170 | 7,686,120 | ||||
| 2024-02-14 | 13G/A | ABUS / Arbutus Biopharma Corporation | 9,503,103 | 9,041,927 | ||||
| 2024-02-14 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 2,012,827 | 2,082,638 | ||||
| 2023-11-21 | 13G | ABUS / Arbutus Biopharma Corporation | 9,503,103 | |||||
| 2023-10-05 | 13G | ESPR / Esperion Therapeutics, Inc. | 7,922,170 | |||||
| 2023-10-02 | 13D | INDV / Indivior Pharmaceuticals, Inc. | 13,670,312 | |||||
| 2023-02-13 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 1,202,622 | 2,012,827 | ||||
| 2022-02-11 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 1,169,163 | 1,202,622 | ||||
| 2021-02-10 | 13G/A | OMEX / Odyssey Marine Exploration, Inc. | 1,169,163 | |||||
| 2020-09-01 | 13G | OMEX / Odyssey Marine Exploration, Inc. |
